US Edition
EU Approves Gilead’s New Injection for Preventing HIV
The European Commission approved Yeytuo for pre-exposure prophylaxis with nearly 100% effectiveness in trials to reduce HIV transmission, which infects 1.3 million people annually.
9 Articles
9 Articles
economiadigital.es
The Objective | Periodismo ethosThe European Commission (EC) has granted a marketing authorisation for Yeytuo (lenacapavir), a six-monthly injectable HIV-1 capside inhibitor developed by Gilead Sciences. The drug has been approved as pre-exposure prophylaxis (PrEP) to reduce the risk of sexual transmission of HIV-1 in adults and adolescents at higher risk of infection and weighing at least 35 kg. It is the first and only PrEP option to be authorised for semi-annual administrat…
The European Commission authorised marketing of a medicinal product in the form of a bilateral injection developed by Gilead Sciences for HIV prevention, announced on March, the company transmitted Reuters.
Gilead Sciences has just announced that the European Commission (EC) has granted a marketing authorisation for Yeytuo (lenacapavir), a six-monthly injectable HIV-1 capside inhibitor. The drug has been approved as pre-exposure prophylaxis (Prep) to reduce the risk of sexual transmission of HIV in adults and adolescents at higher risk of infection and with a minimum weight of 35 kg. It is the first and only option of Prep for approved six-monthly …
Coverage Details
Bias Distribution
- 67% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
